NukeMed

SpectronRx (legally NukeMed Inc.) is a premier radiopharmaceutical contract development and manufacturing organization (CDMO) and isotope producer. Founded in 2003 and headquartered in Indianapolis, Indiana, the company provides end-to-end services for the development, clinical supply, and commercial manufacturing of diagnostic and therapeutic radiopharmaceuticals. SpectronRx is a global leader in the production of high-purity medical isotopes, most notably Actinium-225, using proprietary accelerator-based technology. The company maintains strategic partnerships with numerous biotechnology and pharmaceutical firms, including Clarity Pharmaceuticals and Plus Therapeutics, to advance targeted alpha and beta therapies for various cancers. With multiple state-of-the-art facilities in Indiana and Connecticut, SpectronRx is a critical player in the radiopharmaceutical supply chain, ensuring the delivery of life-saving treatments to patients worldwide.